Week 3 on tirzepatide is when the scale starts looking like a personality. Food noise drops. Protein gets hard. People assume the hard part is over. The hard part is just changing shape: protecting muscle while a dual agonist quietly deletes your appetite.
This is not a dosing guide. If you are on Mounjaro or Zepbound, your clinician owns the titration. The usual starter stretch is several weeks on a low dose before anything steps up. Week 3 is still early. What you track in this window decides whether the weight you lose is mostly fat.
What Week 3 Usually Feels Like
Tirzepatide hits GLP-1 and GIP. Compared with semaglutide, a lot of people see a faster drop in appetite and a slightly different nausea profile. None of that is a reason to pick a drug off a blog. It is a reason the third week often feels like the medication “kicked in” even when you are still on the starter dose.
Common, not universal: smaller meals, skipped snacks, constipation, some nausea around shot day, and a weird energy dip that people read as a sign to stop lifting. The last one is the expensive misread. Compare the two drugs as tracking problems, not as shopping advice, in semaglutide vs tirzepatide.
Stop Letting The Scale Be The Only Chart
Fast early loss is a mix of food, water, glycogen, and some fat. It is a terrible quality signal. If week 3 is the first time you feel in control of eating, it is also the first time protein can silently fall under the floor that keeps muscle around. Set the floor from how much protein you actually need, then treat hitting it as the day's real win.
| Track this | Why week 3 | What “good” looks like |
|---|---|---|
| Shot day, dose, site | Side effects cluster around the injection | A log your clinician can actually read |
| Daily protein | Appetite is down. Protein is the first casualty | Hit the floor, even if dinner is a shake |
| Lifting sessions | Energy feels off. People skip the stimulus muscle needs | 2 to 3 sessions that still happened |
| Nausea, constipation, food noise | Patterns beat a vague “I feel weird” | Severity and timing, not a novel |
| How you feel | Wearable scores will not see this week clearly | A check-in, not a readiness veto |
| Weight | It will move. It still is not composition | Trend, not a daily referendum |
The Muscle Rule For The Starter Month
Do not wait for a DEXA in month six to care. Week 3 is when the habit either exists or does not. Resistance training two or three times a week, protein on the days you barely want lunch, creatine if you and your clinician are fine with it. The evidence and the fear are in the muscle-preservation playbook. Creatine on a GLP-1 is the one-supplement version of the same idea.
If a wearable tells you to rest because sleep staging looked weak, that is a beta score, not a training philosophy. Soreness, dizziness, or vomiting is a different conversation. Skip the session because you are sick. Do not skip it because REM was low.
What To Bring To Your Clinician
Week 4 is when many people talk about the next dose. Show up with a log, not vibes. Shot dates, the worst nausea window, whether protein is actually landing, whether you lifted, and whether constipation is the thing making you miserable. That is augmentation. It is not you titrating yourself.
Mallet is built for this week: shot-day ritual, protein floor, side-effect patterns, lifting, and a Muscle Preservation Score so the scale cannot monopolize the story. See the GLP-1 tracker →
This article is for education, not medical advice. Tirzepatide (Mounjaro, Zepbound) is a prescription medication. Do not start, stop, or change a dose without your clinician. Mallet tracks the journey. It does not prescribe it.